Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.
The observation that depletion or inhibition of regulatory T cells (Tregs) unleashes efficient antitumor effector immune responses that can lead to tumor eradication in mice has opened new perspectives for the development of cancer immunotherapy. The quality and overall efficiency of the effector immune responses induced in the absence of Tregs seem to depend on multiple factors that determine the result of a battle involving effector T cells (Teffs), Tregs and tumor cells. In this study, we investigated the quality of tumor-associated antigens (TAAs) as one such factor. We show that the presence of a strong dominant antigen is required for the induction of effector responses capable of tumor eradication in the absence of Tregs. The sole addition of a dominant antigen on tumor cells does not change tumor growth in unmanipulated mice, but improves tumor eradication rate from a few to almost 100% in the absence of Tregs. This eradication can be shown to result from the recruitment and activation of specific Teffs recognizing this antigen. We also show that the presence of such dominant antigens has the side effect of restricting the breadth of the immune response to other TAAs, which could favor the generation of escape mutant by tumor editing. Taken together, our results highlight the potential, and some requirements for cancer immunotherapy based on Treg depletion. They also show that, ultimately, tumor fate depends on multiple factors that should all be taken into consideration for the design of more efficient immunotherapy.
Bergot
A-S
AS
UPMC Univ Paris 06, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France.
Durgeau
A
A
Levacher
B
B
Colombo
B M
BM
Cohen
J L
JL
Klatzmann
D
D
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D015153:Blotting, Western; D005260:Female; D005434:Flow Cytometry; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000378:metabolism; D007167:Immunotherapy; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology; D015674:Mammary Neoplasms, Animal / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008654:Mesothelioma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D012333:RNA, Messenger
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103
9223321
Nat Immunol. 2002 Nov;3(11):999-1005
12407407
J Exp Med. 2005 Oct 3;202(7):885-91
16186187
Immunol Rev. 1998 Aug;164:111-8
9795769
Nat Immunol. 2007 Apr;8(4):351-8
17322887
Nat Rev Cancer. 2008 Apr;8(4):299-308
18354418
Nature. 1988 Nov 24;336(6197):388-90
3264053
J Immunol. 2006 Jun 1;176(11):6434-42
16709800
J Immunol. 2002 Nov 15;169(10):5796-804
12421960
Nature. 2001 May 17;411(6835):380-4
11357146
Int J Oncol. 2009 Sep;35(3):569-81
19639177
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81
10500201
Science. 2008 Jan 11;319(5860):215-20
18187659
Nat Rev Immunol. 2007 Aug;7(8):645-50
17641664
Int J Oncol. 2006 Feb;28(2):519-25
16391808
J Immunol. 2007 Oct 15;179(8):4969-78
17911581
J Immunother. 2002 May-Jun;25(3):207-17
12000862
J Exp Med. 1994 Jul 1;180(1):347-52
7516411
Nat Med. 2004 Sep;10(9):909-15
15340416
J Immunother. 2004 May-Jun;27(3):184-90
15076135
Eur J Immunol. 1999 Oct;29(10):3295-301
10540341
J Immunol. 1999 Nov 15;163(10):5211-8
10553041
Immunity. 2007 Aug;27(2):203-13
17707129
Eur J Immunol. 2003 Feb;33(2):556-66
12645955
Nat Rev Cancer. 2003 Sep;3(9):666-75
12951585
Nat Med. 2007 Apr;13(4):423-31
17384649
Cell. 1987 Apr 24;49(2):273-80
3494522
J Exp Med. 2001 Sep 17;194(6):823-32
11560997
Int J Cancer. 1992 Dec 2;52(6):881-6
1459729
Int Immunol. 2001 May;13(5):625-32
11312250
J Exp Med. 2002 Mar 4;195(5):657-64
11877489
J Immunol. 1999 May 15;162(10):5838-45
10229818
J Autoimmun. 2004 Mar;22(2):111-4
14987738
Cancer. 2007 Dec 15;110(12):2614-27
18000991
J Clin Invest. 2009 Sep;119(9):2648-62
19652360
J Exp Med. 1994 Jul 1;180(1):25-34
8006585
J Immunol. 2006 Aug 15;177(4):2167-74
16887976
J Immunol. 2000 Jun 1;164(11):5641-51
10820239
Annu Rev Immunol. 1993;11:729-66
7682817
Br J Cancer. 2010 Jan 5;102(1):124-33
19953093
Science. 1991 Dec 13;254(5038):1643-7
1840703
Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6707-11
8022837
Cancer Res. 1999 Jul 1;59(13):3128-33
10397255
J Exp Med. 1995 Jul 1;182(1):75-85
7540658
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19954-9
18042727
J Immunol. 2000 Jun 1;164(11):5782-7
10820256
J Virol. 2002 Jan;76(2):767-73
11752166
J Immunol. 2005 Nov 1;175(9):6169-76
16237114
Cancer Res. 2003 Dec 15;63(24):9007-15
14695219
J Exp Med. 2002 Sep 16;196(6):851-7
12235217
J Immunol. 2002 May 1;168(9):4391-8
11970981
Nature. 2005 Sep 1;437(7055):141-6
16136144
Science. 1996 Mar 22;271(5256):1734-6
8596936